Patient journey: How KesimptaConnect can support your patients
KESIMPTA®▼ (ofatumumab) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.1
For full safety information, please refer to the KESIMPTA Summary of Product Characteristics (SmPC).1
If you are viewing this video outside of a desktop app, please switch to landscape mode or click the expand button on the right-hand side of the video screen.
VIDEO
SmPC, summary of product characteristics.
Reference
KESIMPTA (ofatumumab) Summary of Product Characteristics.
UK | March 2025 | FA-11213993
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
